PM Narendra Modi receiving second vaccine dose at AIIMS Delhi.

Photo: Twitter

PM Modi Receives 2nd COVID Vaccine Jab; Urges All To Take Vaccine

PM Narendra Modi has been administered the second dose of indigenously made COVID vaccine Covaxin at AIIMS-Delhi on April 8. Sharing his vaccination photo on Twitter, PM urged, "If you are eligible for the vaccine, get your shot soon." He had received his first dose of the vaccine on March 1. Reportedly, the Centre has opened the vaccination for everyone aged 45 and above in the third-phase from April 7.

Thu, 08 Apr 2021 - 09:34 AM / by Harsh Vardhan

Tags: Narendra Modi, Covaxin, AIIMS Delhi, Covid-19 Vaccine

Courtesy: The Times of India

Data from trials in other countries found that the efficacy of the vaccine increased when the second dose was given more than six weeks after the first.

Photo: BBC

Doses given 2-3 months apart are more effective, says SII's CEO Adar Poonawalla

CEO of Serum Institute of India, Adar Poonawalla said if a gap of 2-3 months is kept between the first and second dose then the efficacy of Covishield increases to up to 90%. And if the gap is increased for other vaccines it will yield similar results. In March, India decided to increase the interval between the two shots to 8 weeks on the recommendation by the National Expert Group.

Tue, 06 Apr 2021 - 04:37 PM / by Anvitha Shetty

Tags: Covishield vaccine, Covid Vaccination, Covaxin, SECOND WAVE

Courtesy: India Today

Representational photo: Covishield Vaccine.

Photo: The Tribune

Centre Orders Increasing Gap Of Vaccine Interval To 4-8 Weeks

The Centre, on March 22, directed all states and union territories to increase vaccine dose interval from existing 4-6 weeks to 4-8 weeks. Notably, the recommendation based on the vaccine administration's expert committee is only for the 'Covishield' vaccine and not for 'Covaxin'. The Centre's decision is inspired by scientific evidence that shows protection against coronavirus is enhanced if Covishield's second dose is administered between 6… read-more

Mon, 22 Mar 2021 - 05:32 PM / by Harsh Vardhan

Tags: Central Government, COVISHIELD, Covaxin, Coronavirus

Courtesy: Business Standard

SEC says drop clinical trial mode label of covaxin

Photo: Business standard

Expert Committee Asks To Remove 'Trial Mode' Label From Covaxin

The Centre’s Subject Expert Committee has recommended to remove the "clinical trial mode" label from the Bharat Biotech’s COVID-19 vaccine, Covaxin. Reportedly, if the recommendation is considered by the Drugs Controller General of India, it will boost the usage of the vaccine. The recommendation came after Covaxin showed 80.6% efficiency in the late-stage clinical trials. The DCGI’s nod will also not require patients to sign consent form… read-more

Thu, 11 Mar 2021 - 03:15 PM / by Neha Sanjeev

Tags: Covaxin, Bharat biotech, Covid-19 Test, covid-19 testing centres

Courtesy: The Indian Express

COVAXIN

Photo: Business Insider India

Covaxin 81% Effective Against COVID-19 UK Strain In Phase-3 Trials

Indian pharmaceutical giant Bharat Biotech has claimed 81% efficacy against COVID-19 for its vaccine 'Covaxin'. Releasing the phase three clinical data of the vaccine on March 3, the company claimed the vaccine of being effective against the UK variants of the virus. While peer reviews are still awaited, the developer conducted clinical trials on over 25,800 people. Reportedly, Indian drug regulator DCGI earlier approved the Covaxin for… read-more

Wed, 03 Mar 2021 - 06:38 PM / by Nikita Thakur

Tags: Bharat biotech, Covaxin, Health, Covid-19, Coronavirus Vaccines

Courtesy: NDTV

vaccine

Photo: India.com

CoWIN App Not For Vaccine Registration, Only For Administrative Use: Govt

The Centre on March 1 stated CoWIN app has been developed only for administrators to manage the inoculation drive and is not a registration platform for COVID-19 vaccination. It clarified that individuals, who want to get vaccinated, can register themselves through official website. The statement followed the beginning of India's second-phase of mass vaccination which is expected to cover around 27 crore people who are either aged above 60 or… read-more

Mon, 01 Mar 2021 - 02:45 PM / by Ronit John

Tags: Coronavirus, Coronavirus Vaccines, India, Covaxin, CoWIN App

Courtesy: NDTV

Uttar Pradesh Gets The Highest Covid-19 Vaccine In Nation

Photo: The Quint

UP Becomes Most Inoculated State On First Day Of Vaccine Drive

As per reports, Uttar Pradesh has received the highest number of vaccine shots (21,291) after the launch of nationwide COVID-19 vaccination drive. Andhra Pradesh (18,412), Maharashtra (18,328), and Bihar (18169) followed UP in the list of most vaccinated states. The Union Health Ministry declared that 1,91,181 people were vaccinated in 3,352 vaccination sessions. Currently, the Serum Institute of India's Covishield and Bharat Biotech's… read-more

Sun, 17 Jan 2021 - 02:26 PM / by Archita chakraborty

Tags: Covid-19, Covid-Vaccination, Uttar Pradesh, Covaxin

Courtesy: Livemint

Covaxin and Covishield

Photo: India TV News

Delhi: Doctors Request Preference Of Covishield Over Covaxin

In a letter addressed to the medical superintendent, the resident doctors of Delhi's Ram Manohar Lohia Hospital have expressed their apprehension towards Bharat Biotech's Covaxin due to inadequate trial. The doctors instead entreated to use the Serum Institute of India's Covishield vaccine. The decision drew criticism as the panel approved just a day after asking Bharat Biotech to provide more evidence. Reportedly, Covaxin is in its Phase-III… read-more

Sat, 16 Jan 2021 - 06:46 PM / by Ashly Ann Varghese

Tags: Covid -19, Covid Vaccination, Covaxin, COVISHIELD

Courtesy: News 18

Representational photo: Bharat Biotech's COVAXIN

Photo: India TV

Bharat Biotech Assure Compensation For Covaxin's Side Effects

Covaxin manufacturer Bharat Biotech has promised to compensate vaccine recipients if they experience any adverse effects post-vaccination as mentioned in its consent form. However, the company has advised the recipients to follow Covid-19 norms even after inoculation the vaccine. Reportedly, Centre has ordered a supply of 55 lakh doses of Covaxin considering the vaccine's efficacy which is still under the phase-three of clinical trials.

Sat, 16 Jan 2021 - 04:01 PM / by Harsh Vardhan

Tags: Bharat biotech, Covaxin, Covid-19 Vaccine, Health

Courtesy: The Indian Express

Vaccine

Photo: The Times Of India

COVID Vaccines Not Authorised For Children Below 18 Years: Centre

Union Health Ministry has not authorised the administration of two recently approved COVID vaccines on children below 18 years of age. Reportedly, a letter from the ministry has cited the comparative factsheet for the vaccines as the reason behind the decision. Earlier, the Drugs Controller General of India (DCGI) has granted approval for the use of the vaccines - Bharat Biotech's 'Covaxin' and Serum Institute of India's 'Covishield' - on… read-more

Fri, 15 Jan 2021 - 09:37 AM / by Nikita Thakur

Tags: Covid-19, Vaccination, Covid Vaccination, COVISHIELD, Covaxin, Union Health Ministry

Courtesy: Times Now